Summary Session V CLINICAL OUTCOME II

摘要

The fifth session focused on Clinical Outcomes, including seven presentations in which possible Donor-Specific Antibodies (DS A) were evaluated as playing a potential deleterious role in the outcome of allogeneic transplants of different organs. Dr. Marilyn Pollack presented the investigation of the development of DSA after lung transplantation. The analysis included the correlation of C4d staining with DSA. The investigations showed that 8 patients developed DSA; 4 of them had C4d-positive staining. The patients whose biopsies were C4d-negative had anti-DQ DSA. Treatment with different combinations of plasmapheresis/IvIg/Rituximab significantly reduced DSA and correlated with clinical improvement of the episode of antibody mediated rejection. It is suggested that DSA testing should be included in routine post-transplant monitoring protocols.